Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.40 |
| ▸ | MEN1 | O00255 | 1/20 | 0.40 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.38 |
| ▸ | LIPE | Q05469 | 1/20 | 0.37 |
| ▸ | ACHE | P22303 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | AKR1C3 | P42330 | 2/20 | 0.34 |
| ▸ | AKR1C1 | Q04828 | 1/20 | 0.34 |
| ▸ | TMPRSS2 | O15393 | 1/20 | 0.34 |
| ▸ | CNR1 | P21554 | 1/20 | 0.34 |
| ▸ | CNR2 | P34972 | 1/20 | 0.34 |
| ▸ | ESR1 | P03372 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4998689 | 0.96 | PKM (0.41) | PKMKMT2AMEN1ESR2LIPE | |
| SCHEMBL4998285 | 0.90 | LIPE (0.39) | PKMESR2LIPEACHETMEM97 | |
| SCHEMBL4998258 | 0.89 | ADRA1B (0.36) | ESR2LIPEACHEHPGDMAPT | |
| SCHEMBL5004384 | 0.89 | GRM5 (0.38) | ESR2LIPEACHEHPGDMAPT | |
| SCHEMBL14073072 | 0.88 | ABHD6 (0.46) | ESR2LIPEACHEHPGDAKR1C3 | |
| SCHEMBL4989293 | 0.88 | LIPE (0.48) | PKMKMT2AMEN1LIPEACHE | |
| SCHEMBL5004383 | 0.87 | ESR2 (0.36) | KMT2AMEN1ESR2LIPEACHE | |
| SCHEMBL5004394 | 0.86 | LIPE (0.39) | PKMLIPEACHETMEM97SIGMAR1 | |
| SCHEMBL4996227 | 0.86 | KMT2A (0.44) | KMT2AMEN1HPGDMAPTHTT | |
| SCHEMBL4998309 | 0.86 | ADRA1B (0.36) | LIPEACHEHPGDMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | claimed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | NOVO NORDISK A/S (DK) | 2008-09-18 | — | — | US | disclosed |
| EP-1853585-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | Novo Nordisk A/S (DK) | 2007-11-14 | — | — | EP | disclosed |
| WO-2006087309-A1 | 3,4-DIHYDRO-1H-ISOQUINOLINE-2-CARBOXYLIC ACID 5-AMINOPYRIDIN-2-YL ESTERS | NOVO NORDISK A/S (DK) | 2006-08-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080227792-A1 | 3,4-Dihydro-1H-Isoquinoline-2-Carboxylic Acid 5-Aminopyridin-2-Yl Esters | LIPE, LIPC, PNLIP | PKM 1640/4885KMT2A 2803/4885MEN1 3374/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.